Ann: Acrux receives $1.73m advance on FY25 R&D Tax Incentive, page-10

In a post on LinkedIn, former US Food and Drug Administration Commissioner Dr. Robert Califf said, “The FDA as we’ve known it is finished, with most of the leaders with institutional knowledge and a deep understanding of product development and safety no longer employed.”
https://edition.cnn.com/2025/04/01/health/staff-cuts-at-federal-health-agencies-have-begun/index.html

The question is, does this mean existing and new applications just get waved on through by RFK Jr, or are they on ice indefinitely?

Another question is whether the ready to launch product needs any input from the FDA. Approval is granted, but are there any post-approval steps that include FDA? Does there need to be a final inspection or something like that?

And another question is whether the currently launched products will generate enough revenue to cover expenses.

I tend to think ice, and not enough. I don't know about question 2. Not looking good imo.